Advertisement

Lymphopenia predicts response to stereotactic radiosurgery in lung cancer patients with brain metastases

  • Yuping D. Li
  • Jason B. Lamano
  • Gurvinder Kaur
  • Jonathan B. Lamano
  • Dorina Veliceasa
  • Dauren Biyashev
  • Timothy Kruser
  • Orin BlochEmail author
Clinical Study

Abstract

Background

Stereotactic radiosurgery (SRS) can enhance immune activation and improve disease control through stimulation of anti-tumor immunity. However, patients with cancer receiving chemotherapy are often immunosuppressed, which may impact the efficacy of SRS. Here we investigate the relationship between systemic lymphopenia and response to SRS in patients with brain-metastatic lung cancer.

Methods

We reviewed 125 patients with lung cancer brain metastases treated with SRS between January 2014 and May 2017. Complete blood counts from the time of SRS were reviewed, and lymphopenia was defined as absolute lymphocyte count < 1×109 cells/L. Kaplan–Meier survival analysis and cox proportional-hazards models were used to evaluate risks of progression and death.

Results

The median age was 65 years (range 43–86), with 54% female patients. Lymphopenia was present in 60 patients. In univariate analysis, lymphopenic patients had significantly shorter PFS (HR = 2.995, p < 0.0001) and OS (HR = 3.928, p < 0.0001). When accounting for age, gender, smoking history, ECOG score, surgery, and tumor histology in a multivariate model, lymphopenia remained significantly predictive of worse PFS (HR = 1.912, p = 0.002) and OS (HR = 2.257, p < 0.001). Patients who received immunotherapy within 3 months of SRS demonstrated significantly shorter PFS (HR = 3.578, p = 0.006) and OS (HR = 6.409, p = 0.001) if lymphopenic.

Conclusions

Brain-metastatic lung cancer patients with lymphopenia treated with SRS had significantly worse PFS and OS. The effect of lymphopenia was even more pronounced in patients receiving immunotherapy. These data demonstrate the significant impact of deficient immunity on disease control and survival. Lymphopenic patients may benefit from interventions to improve immune function prior to SRS for brain metastases.

Keywords

Lymphopenia Stereotactic radiosurgery Radiation Brain metastasis Immunosuppression Lung cancer 

Notes

Funding

This work was supported by the Howard Hughes Medical Institute Medical Student Research Fellows program (YL) as well as by the National Institutes of Health (NIH)/National Cancer Institute (NCI) Ruth L. Kirschtein National Research Service Award F30 (CA206413; JBL), NIH/NCI R01 (CA164714; OB), and NIH/National Institute of Neurological Disorders and Stroke (NINDS) R00 (NS078055; OB). GK was supported by NIH/NINDS F32 (NS101884).

Compliance with ethical standards

Conflict of interest

The authors report no conflicts of interest.

Supplementary material

11060_2019_3169_MOESM1_ESM.docx (26 kb)
Supplementary material 1 (DOCX 26 kb)

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30.  https://doi.org/10.3322/caac.21387 CrossRefGoogle Scholar
  2. 2.
    Schouten LJ, Rutten J, Huveneers HA, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94:2698–2705CrossRefGoogle Scholar
  3. 3.
    Arvold ND, Lee EQ, Mehta MP, Margolin K, Alexander BM, Lin NU, Anders CK, Soffietti R, Camidge DR, Vogelbaum MA, Dunn IF, Wen PY (2016) Updates in the management of brain metastases. Neuro-Oncology 18:1043–1065.  https://doi.org/10.1093/neuonc/now127 CrossRefGoogle Scholar
  4. 4.
    Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:1037–1044.  https://doi.org/10.1016/s1470-2045(09)70263-3 CrossRefGoogle Scholar
  5. 5.
    Sahgal A, Aoyama H, Kocher M, Neupane B, Collette S, Tago M, Shaw P, Beyene J, Chang EL (2015) Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 91:710–717.  https://doi.org/10.1016/j.ijrobp.2014.10.024 CrossRefGoogle Scholar
  6. 6.
    Serizawa T, Ono J, Iichi T, Matsuda S, Sato M, Odaki M, Hirai S, Osato K, Saeki N, Yamaura A (2002) Gamma knife radiosurgery for metastatic brain tumors from lung cancer: a comparison between small cell and non-small cell carcinoma. J Neurosurg 97:484–488.  https://doi.org/10.3171/jns.2002.97.supplement CrossRefGoogle Scholar
  7. 7.
    Chang EL, Wefel JS, Maor MH, Hassenbusch SJ 3rd, Mahajan A, Lang FF, Woo SY, Mathews LA, Allen PK, Shiu AS, Meyers CA (2007) A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 60:277–283.  https://doi.org/10.1227/01.neu.0000249272.64439.b1 (discussion 283-274)CrossRefGoogle Scholar
  8. 8.
    Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet (Lond, Engl) 363:1665–1672.  https://doi.org/10.1016/s0140-6736(04)16250-8 CrossRefGoogle Scholar
  9. 9.
    Quarmby S, Kumar P, Kumar S (1999) Radiation-induced normal tissue injury: role of adhesion molecules in leukocyte-endothelial cell interactions. Int J Cancer 82:385–395CrossRefGoogle Scholar
  10. 10.
    Steinauer KK, Gibbs I, Ning S, French JN, Armstrong J, Knox SJ (2000) Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int J Radiat Oncol Biol Phys 48:325–328CrossRefGoogle Scholar
  11. 11.
    Nikitina EY, Gabrilovich DI (2001) Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer 94:825–833CrossRefGoogle Scholar
  12. 12.
    Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570.  https://doi.org/10.1126/science.1203486 CrossRefGoogle Scholar
  13. 13.
    Aerts JG, Lievense LA, Hoogsteden HC, Hegmans JP (2014) Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Transl Lung Cancer Res 3:34–45.  https://doi.org/10.3978/j.issn.2218-6751.2013.11.04 Google Scholar
  14. 14.
    Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G (2015) Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28:690–714.  https://doi.org/10.1016/j.ccell.2015.10.012 CrossRefGoogle Scholar
  15. 15.
    Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PCW, Cassier P, Dufresne A, Blay JY (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas and lymphomas. Cancer Res 69:5383–5391.  https://doi.org/10.1158/0008-5472.Can-08-3845 CrossRefGoogle Scholar
  16. 16.
    Lamano JB, Ampie L, Choy W, Kesavabhotla K, DiDomenico JD, Oyon DE, Parsa AT, Bloch O (2016) Immunomonitoring in glioma immunotherapy: current status and future perspectives. J Neurooncol 127:1–13.  https://doi.org/10.1007/s11060-015-2018-4 CrossRefGoogle Scholar
  17. 17.
    Cho O, Oh Y-T, Chun M, Noh OK, Lee H-W (2016) Radiation-related lymphopenia as a new prognostic factor in limited-stage small cell lung cancer. Tumor Biol 37:971–978.  https://doi.org/10.1007/s13277-015-3888-y CrossRefGoogle Scholar
  18. 18.
    Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain metastases. Curr Oncol Rep 14:48–54.  https://doi.org/10.1007/s11912-011-0203-y CrossRefGoogle Scholar
  19. 19.
    Ganss R, Ryschich E, Klar E, Arnold B, Hämmerling GJ (2002) Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Can Res 62:1462–1470Google Scholar
  20. 20.
    Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 < sup > <strong >+</strong > </sup > T cells. J Exp Med 202:907–912.  https://doi.org/10.1084/jem.20050732 CrossRefGoogle Scholar
  21. 21.
    Claude L, Perol D, Ray-Coquard I, Petit T, Blay J-Y, Carrie C, Bachelot T (2005) Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiother Oncol 76:334–339.  https://doi.org/10.1016/j.radonc.2005.06.004 CrossRefGoogle Scholar
  22. 22.
    Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, Forde PM, Brahmer J, Lipson E, Sharfman W, Hammers H, Naidoo J, Bettegowda C, Lim M, Redmond KJ (2018) Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys 100:916–925.  https://doi.org/10.1016/j.ijrobp.2017.11.041 CrossRefGoogle Scholar
  23. 23.
    Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 16:183–194.  https://doi.org/10.1016/j.ccr.2009.06.017 CrossRefGoogle Scholar
  24. 24.
    An X, Ding PR, Li YH, Wang FH, Shi YX, Wang ZQ, He YJ, Xu RH, Jiang WQ (2010) Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 15:516–522.  https://doi.org/10.3109/1354750x.2010.491557 CrossRefGoogle Scholar
  25. 25.
    Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, Widmann WD (2012) Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol 19:217–224.  https://doi.org/10.1245/s10434-011-1814-0 CrossRefGoogle Scholar
  26. 26.
    Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91:181–184.  https://doi.org/10.1002/jso.20329 CrossRefGoogle Scholar
  27. 27.
    Yao Y, Yuan D, Liu H, Gu X, Song Y (2013) Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother 62:471–479.  https://doi.org/10.1007/s00262-012-1347-9 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Neurological Surgery, Feinberg School of MedicineNorthwestern UniversityChicagoUSA
  2. 2.Stritch School of MedicineLoyola University ChicagoMaywoodUSA
  3. 3.Department of Radiation Oncology, Feinberg School of MedicineNorthwestern UniversityChicagoUSA
  4. 4.Department of Neurological SurgeryUniversity of California – DavisSacramentoUSA

Personalised recommendations